USD 18.24
(-3.24%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 2.37 Billion USD | 13.36% |
2022 | 2.02 Billion USD | 3.94% |
2021 | 1.95 Billion USD | 6.72% |
2020 | 1.82 Billion USD | -8.0% |
2019 | 1.98 Billion USD | 3.27% |
2018 | 1.92 Billion USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q3 | 595 Million USD | -3.88% |
2024 Q1 | 586 Million USD | -8.86% |
2024 Q2 | 619 Million USD | 5.63% |
2023 Q3 | 547 Million USD | -1.97% |
2023 FY | 2.3 Billion USD | 13.36% |
2023 Q4 | 643 Million USD | 17.55% |
2023 Q2 | 558 Million USD | 1.09% |
2023 Q1 | 552 Million USD | 6.15% |
2022 Q2 | 507 Million USD | 4.54% |
2022 Q1 | 485 Million USD | -3.39% |
2022 FY | 2.02 Billion USD | 3.94% |
2022 Q4 | 520 Million USD | 0.58% |
2022 Q3 | 517 Million USD | 1.97% |
2021 FY | 1.95 Billion USD | 6.72% |
2021 Q4 | 502 Million USD | 3.93% |
2021 Q3 | 483 Million USD | -4.55% |
2021 Q2 | 506 Million USD | 9.76% |
2021 Q1 | 461 Million USD | -2.54% |
2020 FY | 1.82 Billion USD | -8.0% |
2020 Q3 | 457 Million USD | 0.33% |
2020 Q2 | 455.5 Million USD | 0.0% |
2020 Q1 | 455.5 Million USD | 0.0% |
2020 Q4 | 473 Million USD | 3.5% |
2019 FY | 1.98 Billion USD | 3.27% |
2018 FY | 1.92 Billion USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alcon Inc. | 4.2 Billion USD | 43.584% |
AptarGroup, Inc. | 814.37 Million USD | -191.512% |
Baxter International Inc. | 5.27 Billion USD | 54.97% |
Becton, Dickinson and Company | 6.04 Billion USD | 60.741% |
Haemonetics Corporation | 526.66 Million USD | -350.761% |
Envista Holdings Corp | 1.15 Billion USD | -106.309% |
ResMed Inc. | 1.36 Billion USD | -73.491% |
Teleflex Incorporated | 1.08 Billion USD | -118.96% |
Warby Parker Inc. | 437.22 Million USD | -442.976% |
West Pharmaceutical Services, Inc. | 454 Million USD | -422.907% |